AUS
NZ
UK
CA
USA
IND
Highlights
- Singular Health (SHG) inks a $2 million deal to expand its 3D medical imaging platform in the US
- Secures $8 million strategic placement to fund expansion and innovation
- Partnership with US-based PNS aims to tackle systemic healthcare inefficiencies
Singular Health Group (ASX:SHG), a pioneering medtech innovator, is making significant strides in the US healthcare market through a freshly secured $2 million contract with Florida-based Provider Network Solutions (PNS). The deal is a major milestone in the international rollout of its 3D medical imaging platform, 3DICOM, and underscores the company’s broader ambition to reshape medical imaging and diagnostics globally.
Partnership Aimed at Healthcare Transformation
PNS, a well-established managed service organisation (MSO) overseeing healthcare access for more than 3.7 million members, will initially deploy 1,000 licences of Singular’s 3DICOM MD platform at US$800 per licence. A conditional payment of US$500,000 is also tied to key deliverables under the agreement.
This collaboration has evolved over a year of joint effort between the two companies. It is designed to tackle persistent operational inefficiencies that challenge MSOs across the US, particularly in reducing cost duplication and improving the effectiveness of care delivery. Singular Health’s CEO highlighted how this engagement with PNS is not just a product rollout—it’s a strategic problem-solving initiative within one of the world's most complex healthcare ecosystems.
Funding Fuels Growth Momentum
To complement its expansion efforts, Singular Health has secured $8 million in a strategic placement. Proceeds from this raise are expected to support the continued US rollout of the 3DICOM platform, fund further software development, and boost the company’s working capital position.
PNS and Marin & Sons are participating in this placement, contributing $150,000 each—showcasing their vested interest and confidence in the platform's potential. This funding will serve as a foundation for scaling operations and enhancing the technological backbone that supports Singular’s transformative goals.
Positioning Within the ASX Landscape
As one of the innovative names to watch among Australian-listed medtech firms, Singular Health is carving a niche that could position it favourably among emerging ASX200 stocks. While not yet in the ASX200 index itself, its growing footprint and expanding revenue potential could make it a company of interest for those monitoring rising ASX-listed disruptors.
By focusing on real-world challenges in the healthcare sector and aligning with key partners like PNS, Singular Health continues to solidify its strategic value proposition—not just as a software vendor, but as a solutions provider in a high-impact industry.
